SAN FRANCISCO ( TheStreet) -- The day dawns on day two of the 29th annual J.P. Morgan Healthcare Conference kicks with presentations from Amgen ( AMGN), Genzyme ( GENZ) and Sanofi-Aventis ( SNY).

Here's how this live blog is going to (hopefully) work: I will be posting news updates and analysis throughout the day, live from the presentation rooms and breakout (Q&A) sessions. How can I do this, you might be asking. There's an app for that, literally. I'm using an iPhone live blog app tied into TheStreet's publishing system -- pretty neat.

This J.P. Morgan confab live blog will be similar to the real-time coverage of FDA advisory panels with one big difference: Expect more breaks in between my postings today since I'll be moving around the conference and waiting for companies to present throughout the day. I'll do my best to give you continuous coverage but understand that I'm somewhat at the mercy of the AT&T Network and my ability to type into my iPhone while weaving through crowds and listening to biotech executives speak.

Your best bet is to check back into the live blog several times throughout the day.

Like my previous live blogs, I want to keep today's coverage interactive, so feel free to ping me with comments and questions. I will publish and respond to as many of your comments and questions as I can.

Here's my planned schedule for the day, subject to change, as always. (All times Eastern):

11 am: MAP Pharmaceuticals ( MAPP)
11:30 am: Nektar Therapeutics ( NKTR)
12:30 pm: Seattle Genetics ( SGEN)
1 pm: Aveo Pharmaceuticals ( AVEO)
4:30 pm: Teva ( TEVA)
6:30 pm: Biogen Idec ( BIIB)
7 pm: Keryx ( KERX)

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback